ArticleExperimental physiology2026
Clearance of p16-positive cardiac cells improves age-related cardiac remodeling in mice.
Article in Experimental physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clearance of p16-positive cardiac cells improves age-related cardiac remodeling in mice.Experimental physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Senescent cells are characterized by expression of markers like p16 and secretion of profibrotic and proinflammatory factors. The role of cellular senescence in age-related cardiac remodeling and dysfunction is incompletely understood. This study aimed to: (i) evaluate the effect of p16- positive cell clearance on cardiac function and structure in aging mice, and (ii) assess the role of different cardiac cell-types in the response. Hypertrophy markers, ion channels and calcium handling protein gene expression. Statistical analysis for all panels: one-way ANOVA followed by Tukey's test, significance level P<0.05 (N=6 for each group). Each point represents results from one mouse; bars and horizontal lines are means and SD. NK-ATTAC mice, permitting targeted clearance of p16-positive cells upon exposure to the dimerizing agent AP20187 (AP), were treated with AP or vehicle from 12 to 18 months of age. Cardiac function and structure were assessed with echocardiography, hemodynamics with a Millar catheter. p16-positive cells in various cardiac cell populations were analyzed with Fluorescence-Activated Cell Sorting (FACS) and immunofluorescence imaging. Echocardiography revealed significant attenuation of aging-associated increases in left ventricular mass to diameter at end-diastole (LVDd) and anterior wall thickness at end diastole (LVAWTd) in Aged-AP mice versus Aged-Vehicle. Diastolic dysfunction in vehicle mice normalized with AP treatment. FACS results indicated clearance of p16-positive fibroblasts with AP. Immunofluorescence imaging indicated reduced p16-positive fibroblasts and cardiomyocytes with AP, implicating them in the effects of p16-positive cell clearance on age-related cardiac remodeling. Exposure of cardiomyocytes to senescent fibroblast products led to upregulation of hypertrophy markers, pointing to paracrine effects on cardiomyocytes. This study highlights the potential contribution of senescent fibroblasts and cardiomyocytes to age-related cardiac remodeling. Modulating senescence might provide a new approach to age-related cardiac diseases like heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.